Versiti - Transfusion Medicine & Patient Blood Management Resources | Versiti Diagnostic Laboratories
Explore our service lines

TxMDTransfusion Medicine Resources

Make confident transfusion and patient blood management decisions with expert guidance and practical resources for clinicians and hospital partners.

TxMD™ Transfusion Medicine Program

TxMD is a collaborative, evidence-based transfusion medicine partnership that works alongside hospital teams to strengthen patient safety, improve blood utilization, and advance transfusion practices. Supported by a specially trained TxMD team, hospital partners gain practical guidance, education, and clinical insight to support confident transfusion decision-making across care teams. TxMD support is available at three levels:

Foundational Support

TxMD foundational support provides Versiti blood services clients access to essential transfusion medicine resources, evidence-based guidelines, and stewardship-focused guidance to support safe, appropriate blood use. Included as part of your blood services contract with Versiti, this level of support is designed for hospitals seeking practical education, utilization insight, and answers to routine transfusion and blood bank questions without the need for hands-on clinical integration. 

Customized Partnerships

The Customized TxMD Partnership is designed for hospitals seeking expanded services such as dedicated a Transfusion Safety Officer to improve blood utilization, strengthen operations, and advance quality of care. Versiti works closely with hospital teams to understand workflows, pain points, and priorities, then provide practical guidance and active support to drive meaningful, sustainable improvement.

Patient Blood Management

Patient Blood Management (PBM) is an evidence-based, multidisciplinary approach that helps hospitals improve patient safety, clinical outcomes, and efficiency by reducing unnecessary transfusions and optimizing a patient’s own blood. Through partnership with Versiti, PBM efforts translate data and best practices into consistent, practical transfusion decisions, ensuring the right blood product reaches the right patient, at the right time and for the right reason.

Versiti Guidelines & Resources

Frequently Asked Questions

ABO specific or compatible cryoprecipitate should be selected for pediatric or neonatal transfusions due to small blood volume of these patients. Single units of group AB cryoprecipitate are available from Versiti for neonates.

For adults (or patients >45 kg) any ABO group is acceptable. (See Acceptable ABO/RhD Substitutions for Blood Products – Adults.) Facilities may decide to limit number of units to avoid adverse effects from excessive volume of incompatible plasma.

During transport, the maximum time platelet products may be without agitation is 30 hours and temperature should be as close as possible to 20-24°C.1

During storage, platelet products require continuous gentle agitation at 20-24°C.1 This agitation ensures proper gas exchange for aerobic respiration of the platelets and maintaining pH above 6.2.

In the hospital or laboratory setting, situations may occur where a platelet product is briefly stored without agitation (e.g. operating or procedure room). Studies on the handling of platelet products post manufacturing generally show that interruption in agitation for up to 24 hours does not adversely affect the quality of the platelets. At the end of 5 days, invitro markers are within acceptable limits and pH remains above 6.2. Platelets stored in plasma appear to withstand interruption in agitation better than platelets stored in platelet additive solution unless the additive solution contains bicarbonate or phosphate to regulate the pH. In addition, fewer platelets and larger plasma volumes tolerate the interruptions better, presumably due to less acidic conditions and lower risk for irreversible change to the platelets.2,3

Platelets fared better with shorter, multiple interruptions than a prolonged interruption (i.e., three 8-hour periods without agitation versus one 24-hour period). With shorter interruptions, the impact of the reduced gas exchange is lower and more tolerable for the platelets.3 With apheresis platelet shelf life being 7 days, it is particularly important to limit the duration of each individual interruption of agitation.

References:

  1. Galel SA, et al. AABB Standards for Blood Banks and Transfusion Services, 34th Edition, effective April 1, 2024,
  2. Hunter S, et al. The effect of interruption of agitation on platelet quality during storage for transfusion. Transfusion 2001;41:809-814.
  3. Thomas S. Platelets: handle with care. Transfusion Medicine 2016;26:330–338.

Per CAP TRM.42100 (10-24-2022) and AABB BBTS 7.5.2.4 (33rd edition), when a hemolytic transfusion reaction occurs that is suspected to be related to an attribute of the donor or the blood component, the blood supplier must be notified.

Example: Suspected hemolysis due to passive ABO antibodies from ABO-nonspecific platelet transfusion (Group A recipient receives Group O or Group B apheresis platelet).

Yes. 

The irradiation indicator placed on the unit at the time of irradiation is an internal visual quality control check. The ISBT label is the permanent label for the product. The ISBT component code indicates the product has been irradiated and acceptable for patients who require this blood component modification.

Manufacturers assign a maximum limit for platelet concentration and volume for their apheresis platelet bags to maintain proper gas exchange and optimize platelet viability during storage. When these limits are exceeded but there is insufficient quantity of platelets to manufacture 2 separate platelet products, the single product is stored in a double bag configuration to assure adequate gas exchange to maintain pH above 6.2 and acceptable platelet quality at end of shelf-life.

If a hospital transfusion service desires to combine the two bags, this should be done just prior to issue or release of the platelet product for transfusion. While there is no guidance from the manufacturers or accrediting agencies on an acceptable expiration after combining the bags, an outdate of 24 hours from the time of pooling or the original product expiration, whichever is sooner, is customarily used. This is likely based on the manufacturer’s allowance for the platelets to remain in a single bag for up to 24 hours after collection before the required storage in a double bag.1 Although it would be an uncommon occurrence, if a closed system could not be maintained during the pooling, the expiration of the final product would then be 4 hours from time of pooling per AABB Standards for Blood Banks and Transfusion Services (STD 5.1.9).2

References:

  1. Terumo BCT Recommendations for the ELP Storage Bag. 2017 Terumo BCT, Inc. / PN 306640415E.
  2. Galel SA, et al. AABB Standards for Blood Banks and Transfusion Services, 34th Edition, effective April 1, 2024.